GPCR/G protein

All GPCRs share a common seven trans-membrane structure. GPCRs are associated with heterotrimeric G-proteins which are GTP-binding proteins made of alpha, beta, and gamma subunits. When a ligand binds to GPCR, it activates the attached G-protein, the GDP is replaced with GTP. The activated G-protein then dissociates into an alpha and a beta-gamma complex which activates downstream signaling pathways. These intracellular signaling pathways include cAMP/PKA, calcium/NFAT, phospholipase C, protein tyrosine kinases, MAP kinases, PI-3-kinase, nitric oxide/cGMP, Rho, and JAK/STAT.
GPCRs are one of the most important therapeutic targets for various diseases, over 30% of all modern medicinal drugs target this family. Aberrant GPCR functions are involved in pathological conditions such as neurological, immunological and hormonal disorders. A large number of GPCRs have been identified, but whose ligands are not known, are classified as orphan receptors.
-
B6958 WAY 629 hydrochlorideSummary: 5-HT2C agonist -
C4493 Midodrine (hydrochloride)Summary: prodrug of the α1-adrenergic receptor agonist -
B6906 PNU 142633Summary: 5-HT1D receptor agonist -
C4034 (±)-4-hydroxy Propranolol (hydrochloride)Summary: β1- and β2-adrenergic receptors inhibitor -
B6902 AS 19Summary: Potent 5-HT7 agonist -
C3990 Lofexidine (hydrochloride)Summary: α2-adrenergic receptor agonist -
B6900 SB 258585 hydrochlorideSummary: 5-HT6 receptor antagonist -
C3965 Rilmenidine (hemifumarate)Summary: I1-imidazoline binding site selective ligand and α2-adrenoceptor agonist -
B6898 RitanserinSummary: long-acting 5-HT2 receptor antagonist -
C3786 Guanabenz (hydrochloride)Summary: α2-adrenergic receptor agonist
